

## **II. REMARKS**

### **A. Status of the Claims**

Claims 1-14 were originally filed. Claims 10-14 have been withdrawn as being directed to a non-elected invention. Therefore, claims 1-9 are currently under consideration.

### **B. Response to Restriction Requirement**

In response to the Restriction Requirement imposed by the Examiner, Applicants herein elect, without traverse, the Group I invention, claims 1-9, drawn to a MUC1 chimeric polypeptide comprising a MUC1-EC polypeptide and a human immunoglobulin Fc polypeptide or a human albumin polypeptide and a pharmaceutical composition comprising such. Claims 10-14 have been withdrawn as being directed to a non-elected invention.

Applicants further elect, without traverse, the following 10 MUC1-EC polypeptide sequences in response to the Restriction Requirement imposed by the Examiner:

SEQ ID NO: 1

SEQ ID NO: 3

SEQ ID NO: 5

SEQ ID NO: 9

SEQ ID NO: 11

SEQ ID NO: 15

SEQ ID NO: 17

SEQ ID NO: 19


SEQ ID NO: 25

SEQ ID NO: 27

Each of claims 1-9 reads on the elected sequences.

The Examiner is invited to contact the undersigned attorney at (512) 536-5639 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Monica A. De La Paz  
Reg. No. 54,662  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (fax)

Date: October 31, 2008